VANCOUVER, Sept. 27 /CNW/ - Welichem Biotech Inc. (the "Company") (TSX-V:
WBI), announced today that the Company filed its annual audited financials and
MD & A. The net loss for the three-month period ended May 31, 2007, was
$689,791 (2006 - $754,920), or 1 cent per share (2006 - 3 cents per share).
The net loss for the 1-year period ended May 31, 2007, was $3,201,151 (2006 -
$2,378,867), or 5 cents per share (2006 - 8 cents per share). Detailed
information is available on the SEDAR and Welichem websites (www.sedar.com and
The Company also announced that its Annual and Special General Meeting
will be held at The Simon Fraser University, Diamond Alumni Centre, Room 2065,
515 West Hastings Street, Vancouver, British Columbia (SFU Downtown Campus),
at 1:30 p.m., Pacific Daylight Time, on Monday, October 29, 2007. Detailed
information is also available on the SEDAR and Welichem websites
(www.sedar.com and www.welichem.com).
About Welichem Biotech Inc.
Welichem Biotech Inc. is a publicly-traded biotechnology company
developing therapeutic drugs in the fields of autoimmune diseases and cancer.
ON BEHALF OF THE BOARD
York Yingping Guo
President & Chief Executive Officer
The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of the content of this news
release. This press release contains forward-looking statements that include
our belief as to the potential of our products. Certain risks and
uncertainties such as our ability to successfully commercialize the products
could cause the Company's actual results to differ materially from those in
the forward-looking statements. The Company thus seeks safe harbour.
For further information:
For further information: York Yingping Guo, Tel.: (604) 432-1703, Email:
email@example.com; Yan Chen, Business Development Manager, Tel.: (604)
432-1703, Email: firstname.lastname@example.org